Synergy Offering to Bring in $90M for GI Drug Development

Shaffer, Catherine
April 2013
BioWorld Today;4/11/2013, Vol. 24 Issue 69, p1
The article offers news briefs on financings in the U.S. in 2013. It reports on the $90 million worth of common stock investment of Synergy Pharmaceuticals Inc. to enhance the development of its plecanatide in New York. It notes the potential of plecanatide in treating disorders like constipation-predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC). VistaGen Therapeutics Inc. is expected to get $36 million in investment from Bergamo Acquisition Corp.


Related Articles

  • Financings Roundup.  // BioWorld Today;12/2/2011, Vol. 22 Issue 233, p8 

    The article features the underwritten public offering of New York-based Synergy Pharmaceuticals Inc. for about 1.9 million units of stock at 8 dollars per unit wherein each unit contains two shares of common stock and a warrant to purchase one share.

  • Financings Roundup.  // BioWorld Today;7/8/2009, Vol. 20 Issue 129, p5 

    the article reports on the completion of the final tranche of Synergy Pharmaceuticals Incorporated's private placement. The private placement has a gross proceeds of $7.1 million through the sale of 10.1 million shares of common stock priced at 70 cents a piece. The proceeds will be used by...

  • Financings Roundup.  // BioWorld Today;11/13/2009, Vol. 20 Issue 220, p3 

    The article reports that Synergy Pharmaceuticals Inc. has raised gross proceeds of an aggregate 8.6 million U.S. through the sale of shares of common stock at a price of 70 cents per share, in a private placement. The company intends to use the proceeds from the financing to fund a Phase IIa...

  • Synergy Pharmaceuticals Raises $5.64 Mln in Financing.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p831 

    The article reports on the announcement by the biopharmaceutical company Snergy Pharmaceuticals Inc. in New York that it has raised 5.648 million dollars in financing through the sale of 2,657,882 stocks at 2.125 dollars each. It notes that proceeds from the financing will be used for working...

  • Medical Stock Spotlight.  // MondayMorning;11/19/2012, Vol. 20 Issue 44, p1 

    The article offers pharmaceutical industry news briefs as of November 19, 2012. Synergy Pharmaceuticals Inc. led advancing issues, soaring 1.10 U.S. dollars stock price over the week, to 4.32 U.S. dollars after detailing its plans for developing its bowel drug plecanatide. Gilead Sciences Inc.,...

  • XOMA Raising $39.2M Publicly For Phase II Gevokizumab Trial.  // BioWorld Today;3/7/2012, Vol. 23 Issue 45, p5 

    The article focuses on efforts of Berkeley, California-based XOMA Corp. to raise 39.2 million dollars by selling 29.7 million shares at 1.32 dollars apiece, to support further development of its interleukin-1 candidate gevokizumab and further studies of the compound in noninfectious uveitis.

  • Lpath Inc.  // BioWorld Today;3/7/2012, Vol. 23 Issue 45, p5 

    The article focuses on the sale of 12.4 million Class A common stock shares of San Diego, California-based Lpath Inc. priced at 75 U.S. cents apiece, which brought about 9.3 million dollars to be used for development of product candidates iSONEP and ASONEP, and preclinical development of Lpathomab.

  • Medical Stock Spotlight: Rite Aid Inc.  // MondayMorning;4/15/2013, Vol. 21 Issue 14, p1 

    The article offers news briefs related to the stock prices of several companies in medical care industry. Stock price of Biolase Inc. has jumped to 5.14 U.S. dollars with a gain of 25 percent after clearance of its EPIC 10S soft tissue diode laser by the U.S. Food and Drug Administration (FDA)....

  • SGYP - Synergy Pharmaceuticals Inc - Company Analysis and ASR Ranking Report. Orr, Hunter // Alpha Street Research Reports;Spring2013, p1 

    www.AlphaStreetResearch.com - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison, and our proprietary ASR Ranking indicating Buy/Sell/Hold. Synergy Pharmaceuticals Inc operates in the Biotechnology industry, a subset of the Health Care sector. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics